
Kluwer Patent Blog

HGS v. Eli Lilly, UK Supreme Court, 2 November 2011

Robert Fitt (Brisotws) · Sunday, January 1st, 2012

The UK Supreme Court overturned the decision of the High Court and the Court of Appeal that HGS's patent directed towards Neutrokin, a new protein and member of the ligand superfamily, lacked industrial applicability.


Click [here](#) for the full text of this case. A summary of this case will be posted on <http://www.KluwerIPCases.com>.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2021 Future Ready Lawyer survey** showed that 81% of the law firms expect to view technology as an important investment in their future ability to thrive. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.



Kluwer IP Law

 Wolters Kluwer

This entry was posted on Sunday, January 1st, 2012 at 2:51 pm and is filed under [Case Law](#), [Industrial application](#), [United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.